In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic ...

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher ... a powerful factor that could impact its near-term stock price. The earnings report, which is expected ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

Regeneron stock touches 52-week low at $666 amid market shifts ...